Last reviewed · How we verify
Placebo of TQH2722 injection
Placebo of TQH2722 injection is a Small molecule drug developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control with no active pharmacological mechanism.
At a glance
| Generic name | Placebo of TQH2722 injection |
|---|---|
| Sponsor | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation, TQH2722 placebo injection contains no active pharmaceutical ingredient and produces no direct molecular or therapeutic effect. It is used as a control arm in clinical trials to assess the efficacy and safety of the active TQH2722 drug by comparison.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis (PHASE2)
- A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. (PHASE2)
- To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (PHASE3)
- A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of TQH2722 injection CI brief — competitive landscape report
- Placebo of TQH2722 injection updates RSS · CI watch RSS
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. portfolio CI